A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation alone in Patients with Aggressive B-cell lymphoma: NHL-13

Trial Profile

A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation alone in Patients with Aggressive B-cell lymphoma: NHL-13

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Rituximab (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Dec 2013 Analysis comparing outcomes between male and female patents presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
    • 14 Jun 2013 Final results presented at the 18th Congress of the European Haematology Association.
    • 14 Jun 2013 The last patient received rituximab in September 2010. The study was closed after 148 events had been reached in March 2012. Final analysis was performed in March 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top